PRQR ProQR Therapeutics N.V.

+0.03  (+0%)
Previous Close 17.97
Open 17.88
Price To Book 5.98
Market Cap 696880134
Shares 38,715,563
Volume 210,305
Short Ratio
Av. Daily Volume 297,956

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim positive data presented September 5, 2018. Phase 2/3 pivotal trial to commence 1H 2019.
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
Cystic Fibrosis
Phase 1/2 trial initiation announced June 28, 2018. Interim data late 2018 with full data due 2019.
Epidermolysis bullosa
Phase 1/2 trial to be initiated 2019.
autosomal dominant retinitis pigmentosa (adRP)
Phase 1/2 trial to be initiated in the coming months with data due 1H 2019.
Usher Syndrome Type 2

Latest News

  1. ProQR Announces Strategic Changes to the Management Team and Key New Hires
  2. ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
  3. ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
  4. ProQR to Present at the Evercore ISI HealthConX Conference
  5. Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications
  6. ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
  7. ProQR: 3Q Earnings Snapshot
  8. ProQR Announces Financial Results for the Third Quarter of 2018
  9. ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
  10. ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
  11. Shareholders Should Check The Ownership Structure Of ProQR Therapeutics NV (NASDAQ:PRQR)
  12. ProQR Announces Presentations at the OTS Annual Meeting
  13. Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
  14. ProQR Therapeutics NV Posted 153.7% Returns in the Last Month
  15. Why ProQR Therapeutics N.V. Is Soaring Again Today
  16. 3 Biotech Stocks That Soared This Week: Are They Buys?
  17. ProQR Up More Than 120% on Favorable Eye Disorder Study Data